← 返回

通过带屏蔽小核苷酸的遗传条形码对人 CAR-T 细胞体内命运进行多重转录组分析

英文原题:Multiplexed transcriptomic profiling of the fate of human CAR T cells in vivo via genetic barcoding with shielded small nucleotides.

查看英文原题

Multiplexed transcriptomic profiling of the fate of human CAR T cells in vivo via genetic barcoding with shielded small nucleotides.

PubMed 2023/08/31(内容时间) Nat Biomed Eng Q1 · IF 26.3(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

了解嵌合抗原受体(CAR)T 细胞在体内的命运,有助于优化 CAR-T 细胞设计;这需要对 CAR-T 产品进行永久标记,并在同一微环境中混合培养。本研究报告了一种细胞条形码方法,可利用单细胞 RNA 测序(scRNA-seq)对体内细胞进行多重、纵向分析。该方法名为基于屏蔽小核苷酸的 scRNA-seq(SSN-seq),兼容 3' 和 5' 单细胞分析;通过利用广泛存在的 Pol III U6 启动子,稳定表达带直接捕获序列的小 RNA 条形码,可在细胞输注至分离的整个过程中记录细胞身份。在白血病肿瘤再次攻击小鼠模型中,使用 SSN-seq 追踪 CAR-T 细胞状态动态后发现,用于 CAR-T 细胞离体生产的细胞因子和小分子抑制剂组合,可促进持久性 CD4⁺ 记忆 T 细胞群体在体内扩增。SSN-seq 有助于研究体内细胞状态动态,可能推动过继性细胞疗法开发。

展开英文摘要原文

The design of chimeric antigen receptor (CAR) T cells would benefit from knowledge of the fate of the cells in vivo. This requires the permanent labelling of CAR T cell products and their pooling in the same microenvironment.

Here, we report a cell-barcoding method for the multiplexed longitudinal profiling of cells in vivo using single-cell RNA sequencing (scRNA-seq). The method, which we named shielded-small-nucleotide-based scRNA-seq (SSN-seq), is compatible with both 3' and 5' single-cell profiling, and enables the recording of cell identity, from cell infusion to isolation, by leveraging the ubiquitous Pol III U6 promoters to robustly express small-RNA barcodes modified with direct-capture sequences.

By using SSN-seq to track the dynamics of the states of CAR T cells in a tumour-rechallenge mouse model of leukaemia, we found that a combination of cytokines and small-molecule inhibitors that are used in the ex vivo manufacturing of CAR T cells promotes the in vivo expansion of persistent populations of CD4 + memory T cells. By facilitating the probing of cell-state dynamics in vivo, SSN-seq may aid the development of adoptive cell therapies.

论文信息

作者
Lu X、Lofgren SM、Zhao Y、Mazur PK
第一作者单位
Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.United States
通讯作者单位
Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. pkmazur@mdanderson.org.United States
文献类型
美国 NIH 资助研究 · 非美国政府资助研究 · 美国政府(非公共卫生署)资助研究
期刊
Nature biomedical engineering2023 Sep
原文标识
PubMed 37652986 · DOI 10.1038/s41551-023-01085-3